Foretinib (GSK1363089): ATP-Competitive Multikinase Inhibitor for Cancer Research

Executive Summary: Foretinib (GSK1363089) is a small-molecule inhibitor targeting multiple receptor tyrosine kinases, including VEGFRs and HGFR/Met, with nanomolar potency (IC₅₀ 0.4–9.6 nM) in biochemical assays (APExBIO); it effectively inhibits tumor cell proliferation and migration in diverse cancer cell lines (Schwartz 2022). Foretinib blocks HGF-induced cell motility and induces G2/M cell cycle arrest at nanomolar concentrations (UMassChan eScholarship). In vivo, oral dosing at 30 mg/kg reduces tumor burden in xenograft models. The compound is highly soluble in DMSO (≥31.65 mg/mL) but insoluble in water and ethanol. Foretinib is available for research use from APExBIO as A2974.

Biological Rationale

Receptor tyrosine kinases (RTKs) such as VEGFR and HGFR/Met are central regulators of angiogenesis, tumor growth, and metastasis in human cancers. Dysregulation of these pathways leads to increased tumor vascularization and enhanced metastatic potential (Schwartz 2022). ATP-competitive inhibitors targeting these RTKs are used to dissect signaling dependencies and to suppress tumor progression in preclinical models. Foretinib (GSK1363089) fits this rationale by simultaneously inhibiting multiple RTKs implicated in cancer cell proliferation, survival, and migration (APExBIO).

Mechanism of Action of Foretinib (GSK1363089)

Foretinib is a small-molecule, ATP-competitive inhibitor of several RTKs, including:

• HGF receptor (HGFR/Met)
• VEGFR2 (KDR), VEGFR1 (Flt-1), VEGFR3 (Flt-4)
• Ron, KIT, Flt-3, PDGFRα, PDGFRβ, Tie-2

Biochemical IC₅₀ values for these kinases range from 0.4 to 9.6 nM under standard in vitro kinase assay conditions (pH 7.4, 25°C, ATP 10 μM) (APExBIO). Cellular IC₅₀ for MET inhibition is ~21–23 nM in tumor cell lines such as PC-3 and A549. Foretinib blocks HGF-induced cell motility and migration, and induces cell cycle arrest at G2/M phase, leading to reduced proliferation. This multikinase inhibition disrupts both angiogenic and invasive tumor cell signaling cascades (Schwartz 2022).

Evidence & Benchmarks

• Foretinib inhibits MET, VEGFR2, and Ron with biochemical IC₅₀ values of 0.4–2.2 nM under standard kinase assay conditions (APExBIO).
• In murine B16F10 melanoma, PC-3 prostate, A549 lung, and HT29 colon cancer cells, cellular MET inhibition occurs at 21–23 nM IC₅₀ (APExBIO).
• Oral administration of Foretinib at 30 mg/kg in ovarian cancer xenograft models significantly reduces metastatic nodules and tumor weight compared to vehicle controls (Schwartz 2022).
• Foretinib suppresses HGF-dependent cell migration and induces G2/M cell cycle arrest in vitro at nanomolar concentrations, measured by live-cell imaging and flow cytometry assays (Schwartz 2022).
• Product solubility exceeds 31.65 mg/mL in DMSO at room temperature; the compound is insoluble in water and ethanol (APExBIO).

For a broader mechanistic context, see this review on Foretinib's kinase selectivity—this present article uniquely quantifies in vivo efficacy and real-world assay parameters beyond previous summaries.

Applications, Limits & Misconceptions

Foretinib is widely adopted in oncology research for:

• In vitro tumor cell growth inhibition assays across multiple cancer types.
• Cell motility and invasion assays (HGF/Met and VEGF pathway studies).
• In vivo xenograft and metastasis models in mice.
• Dissection of VEGFR, Met, and related RTK signaling networks.

It is unsuitable for diagnostic or therapeutic use in humans or animals. Foretinib's activity is validated only in research-grade settings—performance may vary based on cell line, assay design, and compound handling (Schwartz 2022).

Common Pitfalls or Misconceptions

• Foretinib is not selective for a single kinase; off-target effects may confound pathway analyses at high concentrations.
• Solubility is DMSO-dependent; attempts to dissolve in water or ethanol will fail and may precipitate the compound.
• Product is not for clinical or veterinary use; research only.
• Long-term storage at room temperature may degrade potency; stock solutions should be kept at -20°C and used promptly.
• Assay conditions (pH, ATP concentration, serum content) can shift observed IC₅₀ values and should be standardized for comparability.

For expanded troubleshooting and protocol optimization, see this guide comparing APExBIO’s Foretinib workflows; our article updates efficacy data and clarifies solubility/handling best practices not emphasized in prior publications.

Workflow Integration & Parameters

• Stock solutions: Prepare in DMSO (≥31.65 mg/mL), store at -20°C, minimize freeze-thaw cycles.
• Working concentrations: Typical in vitro assays use 10–100 nM, adjusted per cell line sensitivity (Schwartz 2022).
• Vehicle controls: Matched DMSO concentrations (≤0.1%) to control for solvent effects.
• In vivo dosing: Oral gavage at 30 mg/kg/day in mouse xenograft models; monitor for toxicity and tumor response.
• Assay endpoints: Cell viability (e.g., MTT, CellTiter-Glo), migration (wound healing, transwell), and apoptosis/cell cycle (flow cytometry).
• Documentation: Reference product batch number (A2974, APExBIO) for reproducibility.

For advanced in vitro/in vivo integration and benchmarking, refer to this mechanistic analysis, which our article extends by including updated dose-response and solubility data for Foretinib (GSK1363089).

Conclusion & Outlook

Foretinib (GSK1363089) is a validated, potent ATP-competitive inhibitor for multikinase modulation in cancer research, with reproducible efficacy in both in vitro and in vivo systems (Schwartz 2022). Its broad kinase inhibition profile and robust experimental benchmarks make it a preferred tool for dissecting RTK-driven malignancies. Proper handling, precise dosing, and awareness of assay variables are essential for experimental reproducibility. For protocol details and product sourcing, see the Foretinib (GSK1363089) APExBIO page.